244 related articles for article (PubMed ID: 26343110)
1. New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer.
Assi R; Temraz S; Shamseddine A; Mukherji D
Curr Drug Targets; 2016; 17(3):290-302. PubMed ID: 26343110
[TBL] [Abstract][Full Text] [Related]
2. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
4. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
Jentzmik F; Azoitei A; Zengerling F; Damjanoski I; Cronauer MV
World J Urol; 2016 Mar; 34(3):297-303. PubMed ID: 26100946
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
Penning TM
J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
[TBL] [Abstract][Full Text] [Related]
6. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
7. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
8. Persistent androgen receptor addiction in castration-resistant prostate cancer.
Schweizer MT; Yu EY
J Hematol Oncol; 2015 Nov; 8():128. PubMed ID: 26566796
[TBL] [Abstract][Full Text] [Related]
9. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
Antonarakis ES
Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
[TBL] [Abstract][Full Text] [Related]
10. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
12. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
14. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
15. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
16. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
17. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
[TBL] [Abstract][Full Text] [Related]
18. Androgen pathway resistance in prostate cancer and therapeutic implications.
Maughan BL; Antonarakis ES
Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250
[TBL] [Abstract][Full Text] [Related]
19. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]